Aktis Oncology, Inc. (AKTS) income statement
AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$16.10−0.21 (-1.29%)
Close on Nov 18, 2026Market cap $895.47MP/E –Yield –
Aktis Oncology, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 14.22
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 194.3%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.95
- Dividend yield
- –
See a number that looks wrong?